HDAC Inhibitor Combination Therapy for Hematological Cancer Relapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, lymphoma, and leukemia are often ineffective in the long term, with high relapse rates and limited therapeutic options for patients who have relapsed or are refractory, highlighting the need for improved therapies that can enhance response rates and reduce relapse.
Innovation Solution
The use of a combination therapy approach involving histone deacetylase inhibitors, such as PXD-101, in conjunction with other chemotherapeutic agents like VEGF antibodies, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, to treat hematological cancers by inducing terminal differentiation, cell growth arrest, or apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (dexamethasone, VAD regimen) are used for multiple myeloma, then initial response can be achieved, but long-term effectiveness is poor with high relapse rates
Solution Approach 1:
The patent combines histone deacetylase inhibitors (PXD-101) with conventional chemotherapeutic agents (dexamethasone, vincristine, doxorubicin, melphalan) to create a multi-modal treatment regimen. This combination targets multiple pathways simultaneously: HDAC inhibition alters chromatin structure and gene expression to induce differentiation and apoptosis, while conventional chemotherapy provides cytotoxic effects. The synergistic interaction between these mechanisms produces sustained therapeutic response and delays relapse in multiple myeloma patients.
2Reliability
If combination therapy with multiple chemotherapeutic agents is used, then therapeutic effectiveness improves, but treatment complexity increases
Solution Approach 1:
The histone deacetylase inhibitor PXD-101 serves multiple therapeutic functions simultaneously: it induces terminal differentiation of plasma cells, arrests cell cycle progression, and triggers apoptosis. This multi-functionality allows a single agent to work synergistically with different components of conventional chemotherapy regimens, effectively managing multiple myeloma through one versatile drug that addresses several pathological mechanisms.
3Ease of operation
If conventional chemotherapy alone is used, then treatment simplicity is maintained, but relapse occurs frequently with limited options for refractory patients
Solution Approach 1:
The patent fundamentally changes the biochemical parameters of cancer cell regulation by inhibiting histone deacetylase enzymes. This epigenetic modulation alters chromatin accessibility, gene transcription patterns, and protein expression profiles in myeloma cells, creating novel therapeutic effects that are distinct from conventional cytotoxic mechanisms. This parameter change provides effective treatment options for relapsed and refractory patients who have failed standard chemotherapy.
Data Source
AI summary
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN® (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.